
Polbionica S.A.
Research and experimental development in natural sciences and engineering
Overview
Polbionica is a leader in 3D bioprinting, developing the world's first functional bionic pancreas made from living cells that can produce insulin and glucagon. The company provides proprietary bioprinting materials, such as TintBionic® and Printiss®, and operates the ResearchLine™ bioreactor for tissue and organ cultivation. Their innovations aim to revolutionize the treatment of chronic diseases, particularly diabetes.
Financials
Revenue history (in k)
From the notes
| Current income tax (CIT due) | $0 |
Filing timeliness
Financial statements were filed on time, on average 7 days early. All were audited by a statutory auditor.
- 202507/07/2026
- 202410/07/2025
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

The Polish-Swiss Forum for Health Dialogue
How to bridge the gap between researchers and entrepreneurs – key question 11. edition of the Polish-Swiss Forum of Dialogue for Health

European Commission Certificate
Nasza innowacja jest chroniona patentem europejskim EP19461559, obejmującym kompleksową procedurę przygotowania bionicznej trzustki, począwszy od przygotowania ECM, który jest podstawą produkowanych bioszkieletów (biotusz A i B) do całego narządu z układem naczyniowym.
Industry
Website technology
- Online shop
- WooCommerce
- Website
- WordPress
Public procurement
No recorded participation in tenders.
The company is the contractor in 2 public sector contracts, worth USD 1.20k in total. They were signed with 2 public buyers.
| Signed on | Subject | Amount | Public buyer | |
|---|---|---|---|---|
| Sep 22, 2026 | Purchase – UV lamp | $636.68 | Uniwersytet Medyczny Im.Piastów Śląskich we Wrocławiu | |
| Aug 20, 2026 | Chemical reagents for highly specialized research applications | $566.99 | Politechnika Wrocławska |
Authorized Representatives
Manner of representation
In the case of a management board consisting of two or more persons, joint action by two members of the management board is required to make declarations of will on behalf of the company.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2020-06-01.
60 1240 5934 1787 0011 0311 7699
67 1240 5934 1111 0011 0311 7035
94 1240 5934 1111 0011 0311 7325
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 17,554PLN 17,554 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jan 31, 2025 | Transformation registered |
Public aid
8 public aid cases recorded, with a total value of $4,229,621.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 23, 2025 | Aid for research and development projects: industrial research | –– | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jul 23, 2025 | Aid for research and development projects: experimental development | –– | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Feb 19, 2025 | Aid for projects awarded a Seal of Excellence quality label | –– | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2025-01-01 | 3D bioprinted bionic pancreas as a therapy for type 1 diabetes | $2.6M$2,610,623 | European Funds for a Modern Economy | |
| 2021-07-01 | 3D bioprinted liver tissue with a vascular system as an innovative model for evaluating drug toxicity and the effectiveness of anticancer therapies | $2.3M$2,271,472 | Operational Programme Smart Growth | |
| 2020-06-01 | Preparation of an application to the Horizon 2020-Accelerator programme to develop a unique technology for 3D printing a bionic pancreas. | $15,129$15,129 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Human Biome S.A. | $583,508.16 | human-biome.com | ||
| Piero Composites sp. z o.o. | $337,002.08 | pierocomposites.pl | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| SKIN Lab International sp. z o.o. | $295,930.15 | skinlab.pl | ||
| Albi-Tech sp. z o.o. | $288,607.46 | albi-tech.pl | ||
| F1 Pharma S.A. | $272,113.66 | f1pharma.pl | ||
| Phage Consultants sp. z o.o. | $193,130.82 | phageconsultants.com | ||
| 123d sp. z o.o. | $192,464.77 | 123d.pl | ||
| Eduroco sp. z o.o. | $126,644.58 | eduroco.pl | ||
| Awtm sp. z o.o. | $123,062.45 | awtm.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-10-08 | Share capital increase (540,000.00 PLN → 546,669.00 PLN) | |
| 2025-08-13 | Address change (Aleja Prymasa Tysiąclecia 79a, 01-242, Warszawa → Ul. Nowy Kisielin-A. Wysockiego 1, 66-002, Zielona Góra) | |
| 2025-01-21 | Entered in the register |
FAQ
Last updated: 2026-09-08